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Inhibition of O‑GlcNAc transferase 
activates tumor‑suppressor gene 
expression in tamoxifen‑resistant 
breast cancer cells
Anna Barkovskaya1,2,9, Kotryna Seip2, Lina Prasmickaite2, Ian G. Mills3,4,5, 
Siver A. Moestue6,7 & Harri M. Itkonen3,8*
In this study, we probed the importance of O‑GlcNAc transferase (OGT) activity for the survival of 
tamoxifen‑sensitive (TamS) and tamoxifen‑resistant (TamR) breast cancer cells. Tamoxifen is an 
antagonist of estrogen receptor (ERα), a transcription factor expressed in over 50% of breast cancers. 
ERα‑positive breast cancers are successfully treated with tamoxifen; however, a significant number 
of patients develop tamoxifen‑resistant disease. We show that in vitro development of tamoxifen‑
resistance is associated with increased sensitivity to the OGT small molecule inhibitor OSMI‑1. 
Global transcriptome profiling revealed that TamS cells adapt to OSMI‑1 treatment by increasing the 
expression of histone genes. This is known to mediate chromatin compaction. In contrast, TamR cells 
respond to OGT inhibition by activating the unfolded protein response and by significantly increasing 
ERRFI1 expression. ERRFI1 is an endogenous inhibitor of ERBB‑signaling, which is a known driver 
of tamoxifen‑resistance. We show that ERRFI1 is selectively downregulated in ERα‑positive breast 
cancers and breast cancers driven by ERBB2. This likely occurs via promoter methylation. Finally, 
we show that increased ERRFI1 expression is associated with extended survival in patients with 
ERα‑positive tumors (p = 9.2e−8). In summary, we show that tamoxifen‑resistance is associated with 
sensitivity to OSMI‑1, and propose that this is explained in part through an epigenetic activation of the 
tumor‑suppressor ERRFI1 in response to OSMI‑1 treatment.
Breast cancer is the most common cancer in women and over half of all breast cancers express estrogen receptor 
α (ERα), a nuclear hormone  receptor1. Standard treatment in this patient group includes anti-ERα therapies, such 
as  tamoxifen2. Resistance to this type of treatment is a significant challenge in the clinical setting, and results in 
the development of a more aggressive disease. One of the best understood mechanisms of tamoxifen-resistance 
is increased activity of receptor tyrosine kinases, most notably epidermal growth factor receptor (EGFR) and 
erb-b2 receptor tyrosine kinase 2 (ERBB2, Her2)3–5. Despite significant efforts, discovery of targeted therapies 
against tamoxifen-resistant breast cancer remains a significant  challenge6,7.
O-GlcNAc transferase (OGT) has emerged as a candidate drug target in breast cancer. OGT is overexpressed in 
breast cancer patient tumor  samples8–11, while genetic silencing of OGT decreases breast cancer cell proliferation 
both in vitro and in vivo12,13. In addition, it has been shown that OGT overexpression promotes tumor initiation 
in mouse models of breast  cancer14. Conversely, OGT is not essential for the survival of post-mitotic normal 
mammalian  cells15–18. These features position OGT as a candidate target for anti-breast cancer therapy.
OGT functions as a signaling hub that integrates nutrient status of the cell and modifies target proteins 
 accordingly19,20. OGT’s co-substrate is produced via hexosamine biosynthetic pathway, which consumes 
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glucose, glutamine, acetyl-CoA and ATP, the key metabolites involved in  proliferation21. Depending on nutrient 
availability and other cues, OGT glycosylates intracellular proteins on serine and threonine residues, competing 
with protein kinases for  substrates22. However, unlike hundreds of kinases, OGT is the solo enzyme catalyzing 
all protein glycosylation in the nucleus and cytoplasm. This unique role positions OGT as a major signaling hub.
Pharmacological inhibition of OGT represents a potential strategy to target this enzyme for cancer therapy. 
Several groups have developed compounds that alter O-GlcNAc signaling, but many of the compounds such 
as Alloxan (uracil mimic)23 and BAGDP (N-acetylgalactosamine mimic)24 require utilization of millimolar 
doses. An intriguing strategy is to use a synthetic carbohydrate precursor (Ac4-5SGlcNAc) that is converted 
into glycosyltransferase inhibitor within the  cell25. This compound decreases aggressive phenotype of breast 
cancer  cells26,27. However, a major limitation of this compound is that it additionally targets other carbohydrate 
processing enzymes. OSMI-1 is an OGT small molecule inhibitor that does not significantly affect other 
glycosyltransferases and is active in low micromolar  doses28. We recently used OSMI-1 to demonstrate that 
triple-negative breast cancer cells are sensitive to OGT  inhibition29. Overall, OSMI-1 represents an excellent 
tool compound to study OGT biology in vitro, and to discover possible strategies for anti-breast cancer therapy.
In this study, we used OSMI-1 to probe the importance of OGT activity for the survival of tamoxifen-resistant 
breast cancer cells in an isogenic cell line pair: Tamoxifen sensitive ERα-positive MCF7 cell line (TamS), and its 
tamoxifen-resistant derivative (TamR). We find that TamR cells show increased sensitivity to OSMI-1 relative 
to the parental line. Further, global transcriptome profiling shows that OSMI-1 treatment induces expression of 
the endogenous inhibitor of RTK-signaling, ERRFI1. The ERRFI1 promoter is hyper-methylated in breast cancer 
patient samples, which is associated with low expression levels and poor prognosis. Our findings suggest a link 
between OGT and ERRFI1 signaling, pointing to OGT as a possible therapeutic target in a significant subset of 
breast cancer patients.
Results and discussion
Tamoxifen resistant breast cancer cells are sensitive to OSMI‑1. Here we compare the role of 
OGT in tamoxifen-sensitive MCF7 breast cancer cell line (TamS), and a previously established MCF7-derived 
tamoxifen-resistant cell line (TamR)5. First, we confirmed the tamoxifen-resistant phenotype of the TamR cells 
using relative cell number (DNA content) as a read-out (Suppl. Figure 1A). Notably, we did not observe significant 
differences in tamoxifen-sensitivity when using an MTS assay (relies on the activity of the NAD(P)H-dependent 
dehydrogenase enzymes, Suppl. Figure  1B). Next, we evaluated the overall O-GlcNAcylation and noted that 
both TamS and TamR have similar levels (Suppl. Figure  2A). The OGT small molecule inhibitor (OSMI-1) 
decreased total-O-GlcNAc by 30% in both cell lines (Fig. 1A). This effect was similar to treatment with another 
OGT inhibitor  ST04584930. We also noted that OGT expression was increased in response to OSMI-1 treatment 
(Suppl. Figure 2B). Upregulation of OGT in response to OGT inhibition has been previously observed, and likely 
represents one of the compensation mechanisms that cells employ to restore O-GlcNAc  homeostasis31–33. These 
data demonstrate on-target inhibition by both OSMI-1 and ST045849 in breast cancer cells. 
Next, we assessed the importance of high OGT activity for proliferation of TamS and TamR cells using MTS 
assay relying on metabolic activity of cells and live-cell imaging to generate proliferation curves. OSMI-1 and 
ST045849 dose-dependently decreased viability of both cell lines as determined using the MTS assay (Fig. 1B). 
Interestingly, TamR cells were significantly more sensitive to both OSMI-1 and ST0145849 than the parental 
TamS cells, with OSMI-1-EC50 value of ~15 µM in TamR and ~ 40 µM in TamS. Live-cell imaging showed that 
OSMI-1 treatment blocks proliferation of TamS and TamR cells (Suppl. Figure 2C). Based on these data, we 
conclude that the metabolic activity of TamR cells is more sensitive to OGT inhibition, and moved on to explore 
the basis for this differential sensitivity.
OGT inhibition has been shown to significantly alter the transcriptional program of  cells31,34, and we 
determined whether the differential sensitivity of TamR cells against OSMI-1 is reflected at the mRNA levels. 
OGT inhibition can suppress cancer cell proliferation in part through induction of DNA damaged-induced 
transcript 3 (DDIT3, also known as CHOP)13 and downregulation of mRNAs encoding for cell specific 
transcription factors that support cell  proliferation33. One of the most prominent effects of OGT inhibition is 
compensatory upregulation of the gene encoding for OGT  itself31–33,35. In accordance with these reports, we 
found that OSMI-1 causes increased expression of OGT and DDIT3 in both TamS and TamR cells while ERα 
is downregulated (Fig. 1C). These effects are more prominent in TamR cells, suggesting that changes in the 
transcriptional program could underpin the differential sensitivity to OSMI-1.
OSMI‑1 induces transcriptional program indicative of chromatin silencing in TamS cells. To 
further explore the mechanism of increased sensitivity of TamR cells to OSMI-1 treatment, we performed a 
microarray transcriptomic analysis. We used RT-qPCR to validate the expression of genes that were among 
the top most downregulated (Ribonucleotide Reductase Regulatory Subunit M2 (RRM2), Thymidine Kinase 
1 (TK1) and Deoxyuridine Triphosphatase (DUT)) and most upregulated (Asparagine Synthetase (ASNS), 
Aldolase, Fructose-Bisphosphate C (ALDOC) and Solute Carrier Family 3 Member 2 (SLC3A2), Suppl. Table 1). 
Expression of all six genes was differentially regulated by two to sixfold in response to OSMI-1 treatment, 
validating the microarray data (Fig. 2A).
Having established the quality of the microarray data, we performed pathway enrichment analysis to identify 
the key processes affected by the OSMI-1 treatment. OSMI-1 caused similar changes in the transcriptome of 
both cell lines and the top most upregulated pathways included steroid hormone biosynthesis and lysosomal 
degradation, which likely represent pro-survival adaptations to OSMI-1 treatment (Suppl. Table 1). Both TamS 
and TamR cells shared a number of significantly downregulated pathways including cell cycle, DNA replication 
and RNA processing (Suppl. Table 1, adjusted p-value < 0.05). In particular, we found the transcripts related to 
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cell cycle progression to be highly enriched (Fig. 2B and Suppl. Table 1). To verify the impact of OGT inhibition 
on cell cycle regulation, we performed cell cycle analysis. OSMI-1 decreased the number of cells in S-Phase 
and also caused a modest, but not significant, accumulation of cells in the G2-M phase (Fig. 2C). These effects 
are in agreement with a previous study describing the importance of OGT for successful progression through 
 mitosis36. However, cell cycle distribution in response to OSMI-1 was similar in both cell lines, and therefore 
cannot explain the increased sensitivity of TamR cells to the compound.
To explain the differential sensitivity of the cell lines to OGT inhibition, we focused on the mRNAs that were 
exclusively affected either in the TamS or TamR cells. We noted prominent downregulation of pathways related to 
DNA repair in TamS, and to a lesser extend also in TamR cells in response to OSMI-1 (Suppl. Table 1). The TamR-
specific downregulated pathways were predominantly associated with metabolic processes such as amino acid 
degradation and fatty acid elongation (Suppl. Table 1). We have previously shown that inhibiting OGT leads to 
metabolic vulnerabilities by suppressing glycolytic activity, which sensitized cancer cells to inhibitors of oxidative 
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Figure 1.  OGT inhibition reduces viability of breast cancer cells. (A) Total protein O-GlcNAcylation in TamS 
and TamR breast cancer cells after 24 h of treatment with OGT inhibitors—ST045849 or OSMI-1. Densitometry 
was used to determine the intensity of the signal. (B) Cell viability measured with MTS assay, following 72 h 
of treatment with increasing doses of either ST045849 or OSMI-1. An average of at least 3 biological replicates 
with SEM are shown. Significance of the data was evaluated using unpaired t-test, *-p ≤ 0.05, **-p ≤ 0.01. (C) 
RT-qPCR based evaluation of mRNA abundance following 24 h of OGT inhibition with either ST045849 or 
OSMI-1 at 40 μM dose. Average of three biological replicates with SEM are shown.
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 phosphorylation33. This suggests that the enhanced sensitivity of TamR cells to OSMI-1 may be explained, in 
part, through the impaired ability to compensate for the metabolic stress induced by OGT inhibition. Tamoxifen 
treatment is known to impose a selection pressure for metabolic adaptations that support the emergence of 
 resistance37,38, and in addition to targeting ERα, tamoxifen also suppresses oxygen consumption by blocking 
complex 1 of the electron transport chain, increases glycolysis and alters lipid  metabolism39. It is possible that 
the increased sensitivity of TamR cells to OGT inhibitors is in part a side effect of these adaptations.
Next, we focused on the genes that were selectively upregulated in either of the cell lines as these could explain 
the differential sensitivity towards OSMI-1. We noted a strong activation of the transcriptional networks related 
to endoplasmic reticulum stress specifically in TamR cells (Suppl. Table 1). The most enriched pathway in TamS 
cells was ‘Chromatin silencing’, which was completely absent in TamR cells (Fig. 3A and Suppl. Table 1). When 
inspecting the mRNAs that explain the enrichment of this pathway, it became obvious that increased expression 
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Figure 2.  OGT inhibitor OSMI-1 decreases the percentage of breast cancer cells in S-Phase. (A) Validation of 
the microarray data using RT-qPCR. Cells were treated as indicated for 24 h, mRNA was isolated and used for 
RT-qPCR with select primers. Data shown is an average of four biological replicates with SEM and is normalized 
to DMSO treated control. (B)  KEGG55–57 pathway enrichment analysis for the top most downregulated genes 
in TamS and TamR cells (Log2(FC) atleast − 0.5). (C) Cell cycle distribution of TamS and TamR cells after 
treatment with 40 μM OSMI-1 for 24 h. Data shown is an average of three biological replicates with SEM. 
Statistical analysis was performed using t-test, *-p ≤ 0.05.
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detected, 49 were increased in the TamS cells but remained largely unchanged in the TamR cells (Fig. 3B,C). This 
transcriptional response is the most striking differential response to OGT inhibition between TamS and TamR 
cells, and its mechanistic implications warrant further interrogation.
Increased expression of histone mRNAs has been previously demonstrated in response to bromodomain 
inhibitor-induced decrease in chromatin  accessibility40. We hypothesized that if chromatin accessibility is altered 
in response to OGT inhibition in TamS cells, genes driven by super-enhancers would be most acutely affected 
by this treatment. To test this, we selected all super-enhancers in MCF7 cells 41 and assessed if the expression of 
associated mRNAs changes in response to OGT inhibition. Genes driven by super-enhancers were preferentially 
downregulated in response to OGT inhibition in the TamS cells when compared to the TamR cells (Suppl. 
Table 1). We have previously shown that chromatin O-GlcNAcylation overlaps with sites of active transcription 
and that OGT inhibition results in decreased chromatin accessibility in prostate cancer  cells42. To fully elucidate 
the effects of OGT inhibition on chromatin accessibility in breast cancers cells, more direct assays such as FAIRE- 
or ATAC-seq are needed. While these experiments are essential to perform in follow-up studies, microarray data 
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Figure 3.  OGT inhibitor OSMI-1 induces transcriptional program indicative of chromatin silencing in 
tamoxifen-sensitive breast cancer cells. (A)  KEGG55–57 pathway enrichment analysis for the mRNAs that were 
upregulated exclusively in TamS (Log2(FC) atleast ± 0.5). (B) Histone gene expression in TamS and TamR 
cells after OGT inhibition with 40 μM OSMI-1 for 24 h representing an average of three biological replicate 
experiments analyzed using microarrays. (C) Fold change in the expression of all detected histone genes after 
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focusing on the differentially induced mRNAs, we may be able to identify those that have biologically meaningful 
functions in our model system and can additionally serve as prognostic breast cancer biomarkers.
OSMI‑1 induces expression of a negative regulator of receptor tyrosine kinase signaling in 
TamR cells. Next, we identified the mRNAs that are selectively induced in TamR cells in response to OGT 
inhibition to identify potential tumor-suppressor genes that could function as disease biomarkers. Among five 
mRNAs that were most strongly induced in the TamR but not affected in TamS cells, we identified two genes, 
ERRFI1 (ERBB Receptor Feedback Inhibitor 1) and Ras Related Dexamethasone Induced 1 (RASD1) (Suppl. 
Table 1). OGT is important for the transcriptional regulation of certain  genes43, and we therefore assessed if 
ERRFI1 and RASD1 genes carry an O-GlcNAc mark on their promoters using publicly available  datasets42,44. 
Only ERRFI1 gene had a robust O-GlcNAc mark on its promoter (Suppl. Figure 3). Next, we used RT-qPCR 
to confirm that OSMI-1 treatment increases ERRFI1 expression in TamR cells in a dose-dependent manner 
up to fivefold but does not have any effect in TamS cells (Fig. 4A). In addition, treatment with ST045849 and 
knockdown of OGT induced a significant increase in the ERRFI1 expression in TamR cells (Suppl. Figure 4). 
ERRFI1 encodes a protein that functions as an endogenous inhibitor of ERBB-signaling—a well-established 
mechanism of tamoxifen-resistance3–5. In mouse models, deletion of ERRFI1 results in the development of 
spontaneous  tumors45,46 while in human cells ERRFI1 decreases proliferation of cells that express high levels of 
epidermal growth factor  receptor47. To gain further evidence of the tumor suppressor function of ERRFI1, we 
analyzed ERRFI1 gene dependency score using data available on the Cancer Dependency  Map48,49. Depletion of 
ERFFI1 via CRISPR-mediated knockout increases the proliferation of almost all of the cancer cell lines included 
in this database (Suppl. Figure  5). Both the literature and CRISPR-data are consistent with ERRFI1 being a 
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Figure 4.  High expression of ERFFI is associated with positive prognosis in breast cancer patients. (A) 
RT-qPCR based evaluation of ERFFI1 expression after 24 h treatment with either DMSO or OSMI-1. Data 
shown is an average of four biological replicates with SEM and is normalized first to a house-keeping gene 
and then relative to DMSO treated control. Significance of the data was evaluated using unpaired t-test. (B, C) 
Expression and promoter methylation of ERFFI1 in breast cancer subclasses. The graphs were generated using 
UALCAN  tool58 and the TCGA dataset. (D) Survival in breast cancer patients with low or high expression of 
ERFF1 mRNA. The plot was generated using Kaplan–Meier Plotter (mRNA gene chip, all probe sets for the 
gene, autoselect best cutoff and other settings as default)59.
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of this manuscript, characterization of TamS and TamR cells response to OGT inhibition, are required to assess 
if ERRFI1 is a bona fide tumor-suppressor. Nevertheless, these data suggest that the loss of ERFFI1 expression 
may be associated with the development of aggressive breast cancer.
We used publicly available datasets to evaluate ERRFI1 expression and association with cancer progression. 
ERRFI1 mRNA was downregulated in 17 separate breast cancer gene expression datasets available through 
 Oncomine50, but was not prominently altered in other cancers, suggesting that this gene may be specifically 
associated with breast cancer (Suppl. Figure 6). Interestingly, ERRFI1 expression was significantly lower in ERα-
positive (luminal) breast cancer patient samples when compared to either normal tissue or triple-negative breast 
cancer (TNBC) samples (Fig. 4B). In addition, we noted that ERRFI1 is downregulated in ERBB2-positive breast 
cancers, a disease driven by this receptor tyrosine  kinase51. Overall, these data imply that ERRFI1 functions as a 
tumor suppressor in breast cancers driven by ERα and/or ERRB-signaling.
We investigated the mechanistic basis for the loss of ERRFI1 expression in breast cancer patient samples. 
ERRFI1 expression can be controlled via DNA  methylation51 and OGT is known to modify proteins that regulate 
chromatin  accessibility20. ERRFI1 promoter methylation was significantly higher in normal breast cancer tissue 
and TNBC patient samples when compared to the luminal breast cancer and ERBB2-positive breast cancer 
samples (Fig. 4C). High promoter methylation was associated with decreased ERRFI1 expression (Fig. 4B,C). 
Next, we asked if the differential expression of ERRFI1 has a prognostic value for breast cancer patients. We 
found that in luminal type A breast cancer patients, high expression of ERRFI1 was very strongly associated 
with a positive outcome (9.2e−08, Fig. 4D). In addition, increased expression of ERRFI1 was also significantly 
associated with good prognosis in patients treated with tamoxifen (Suppl. Figure 7).
To conclude, we report that tamoxifen-resistance is associated with increased sensitivity to OGT inhibition by 
OSMI-1 (Fig. 1B). We have previously demonstrated that TamS cells can be sensitized to OSMI-1 by  tamoxifen29, 
and in this study we show that tamoxifen-resistant breast cancer cells are also dependent on high OGT activity. 
Even though we are not able to describe the specific mechanism, activation of the anti-proliferative transcriptional 
program specifically in endocrine-resistant breast cancer cells represents an intriguing strategy for cancer therapy. 
It has become apparent that OGT inhibitors can sensitize cancer cells to targeted therapies, such as inhibitors 
of phosphoinositide 3-kinase  signaling52,  glycolysis53 and  proteasome54. It is not clear why a decrease in OGT 
activity sensitizes cancer cells to different treatments, and mechanistic understanding of this will enable more 
rational design of combination therapies with compounds targeting OGT. Results presented here suggest that 
targeting OGT may enhance the efficacy of ERBB receptor tyrosine kinase (RTK) inhibitors in cancer cells 
dependent on these RTKs. Based on our findings and previous data from others, we conclude that OGT functions 
as a context-dependent regulator of transcription.
Materials and methods
Cell culture. MCF7 cell line (referred to as TamS in this manuscript) was purchased from ATCC (Rockville, 
MD). TamS was cultured in DMEM (Sigma Aldrich) supplemented with 10% fetal bovine serum (FBS). TamR 
cells were a kind gift from Dr Julia Gee and Professor Robert I Nicholson (University of Cardiff), and have 
been previously  described5. TamR cells were propagated in DMEM without phenol red (Thermo Fischer), 
supplemented with 5% charcoal stripped FBS. Cell lines were maintained in humidified incubators at 37 °C and 
were routinely tested for mycoplasma contamination.
Western blotting. For western blotting analysis, TamS and TamR cells were seeded into 6-well plates, using 
1.8 × 105 cells per well in their respective media. Cells were treated with increasing concentrations of ST045849 
(obtained from TimTec) and OSMI-1 (gift from Professor Suzanne Walker, Harvard Medical School, or obtained 
from Sigma Aldrich) the next day and collected on ice 24 h after the start of the treatment. Immunoblotting was 
performed using RL2 antibody (for total O-GlcNAcylation) (Abcam, ab2739), OGT (Cell Signalling, #5368) and 
β-actin antibody (Cell Signalling, #4967). Band intensity was quantified using ImageJ software.
Cell cycle analysis. TamS and TamR cells were collected on ice following 24 h of treatment with 40 µM 
dose of OSMI-1 compound, or DMSO. Samples were immediately fixed in 100% ice-cold methanol and placed 
in − 20 C° for storage. Samples were washed in cold PBS and stained with 1.5 µg/ml Hoechst 33258 in PBS for 
30 min at 37 °C. Cell cycle analysis was then performed on LSR II flow cytometer (BD Bioscience, San Jose, CA).
MTS viability and crystal violet assays. Tamoxifen (Sigma, Prod. No. T5648) was freshly prepared just 
prior to the experiment. MTS (CellTiter 96  AQueous Non-Radioactive Cell Proliferation Assay, Promega) was 
added to the cells at 1:5 dilution in growth media for 1–2 h at 37 °C. Absorbance at 490 nm was then measured 
using a Multilabel Counter Wallac plate reader. Results were corrected for background and normalized to 
DMSO-treated controls. For Crystal violet assay, cells were washed twice with PBS, fixed with ice cold 70% 
MeOH for 2 min followed by ice cold 100% MeOH for 10 min. After the cells dried out 0.05% crystal violet 
solution was applied for 10  min. After staining, cells were washed twice with distilled water and let to dry. 
For Crystal violet dissolution and measurement, 50 µL/well of 10% acetic acid was added, followed by 15 min 
de-stain on a plate shaker and absorbance was measured at 590 nM by the plate reader.
Microarray data. Microarray profiling was performed at the NTNU Genomics Core Facility using Illumina 
HT-12 BeadChip arrays in biological triplicates.
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RNA isolation/RT‑qPCR. Cells were collected following 24  h of treatment. mRNA was isolated using 
Illustra RNA spin mini kit (GE healthcare, Chicago, IL). cDNA was prepared using the qScript cDNA Synthesis 
Kit in accordance with the supplier’s instructions (Quanta Biosciences, Gaithersburg, MD). qPCR reactions were 
set up using 2.5 µl of 10 ng/µl stock cDNA, 2.5 µl of 1 µM forward and reverse primer mix and 5 µl of Fast SYBR 
Green master mix (Thermo Fischer Scientific). The following primers were used for gene expression analysis: 
OGT forward: CAG CAT CCC AGC TCA CTT , reverse: CAG CTT CAC AGC TAT GTC TTC; OGA forward: CGA 
GTG AAC ATT CCC ATC ACT, reverse: CCC AAA GGA GCA CAG ATG TT; DDIT3 forward: CTG GGG AAT 
GAC CAC TCT GT, reverse: CTT GGC TGA CTG AGG AGG AG; ERα forward: TGG GCT TAC TGA CCA ACC TG, 
reverse: CCT GAT CAT GGA GGG TCA AA; RRM2 forward: TTT AGT GAG CTT AGC ACA GCG GGA , reverse: 
AAA TCT GCG TTG AAG CAG TGA GGC; TK1 forward: GCC GAT GTT CTC AGG AAA AAGC, reverse: GCG 
AGT GTC TTT GGC ATA CTTG; DUT forward: CTA TGG AGA AAG CTG TTG TGAAA, reverse: TTG CAG 
CCA AGC CTG ACC; ASNS forward: ATC ACT GTC GGG ATG TAC CC, reverse: CTT CAA CAG AGT GGC AGC 
AA; ALDOC forward: CGT CCG AAC CAT CCA GGA T, reverse: CAC CAC ACC CTT GTC AAC CTT; SLC3A2 
forward: ATT GGC CTG GAT GCA GCT GC, reverse: ACA GCC CCT GGG ATG TCA GG; ERRFI1 forward: TGC 
TGA TGT GAC CTC TGG AA, reverse: CCT TGT GTT GCT GGT TCC TA; TBP forward: GCC AGC TTC GGA GAG 
TTC TG, reverse: GCA CGA AGT GCA ATG GTC TTT. qPCR was run on a Bio-Rad CFX Connect Real Time PCR 
machine (Bio-Rad, Hercules, CA).
Knockdown of OGT using siRNAs. Reverse siRNA knockdowns were performed using two OGT 
siRNAs: s16094 and s16095 (Thermo Fisher Scientific, Rockford, IL). 2.5 µL of 10 nM siRNA was mixed with 
2 µl of Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA) in 360 µl Opti-MEM reduced serum medium 
(Thermo Fisher Scientific) per well. The mixture was incubated for 20 min in room temperature and placed into 
6-well culture plates. The cells were added to the plates in 2 ml of respective cell culture media, using 1 × 105 cells 
per well. Cells were collected for RNA extraction 72 h later.
Data availability
The data has been deposited to GEO with the accession number GSE148186.
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